Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 60

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 60
---
,456 in 2023. The decrease was primarily driven by the recognition of a Derivative Gain of $2.151, 755 in 2023 as opposed to a Derivative Loss of $(4,091) in recognized in 2024. Additionally, the Company recorded higher amortization of discount of $(28,998) related to debt instruments, compared to $(864) in the prior year. Interest expense also rose to $(72,445) due to increased borrowings, while financing fees decreased to $(145,500) as opposed to $(250,000) in 2023. Financing fees in both instances were attributable to Common Shares issued in conjunction with Promissory Notes.

<div align='center'>43</div>

The reduction in financing fees partially offset the rise in interest expenses and derivative losses, but the net impact was a significant decline in other income, highlighting the volatility associated with fair value remeasurements and debt-related costs.

Net Loss

The Company recognized an Operating Loss of $ 417,221 during the twelve months ended September 30, 2024 whereas the Company recognized an Operating Loss of $ 686,950 for the same period ended 2023. The reduction in operating loss is for the reduction of Consulting and Professional Fees services for the period.

Net Loss is $ 668,255 for the twelve months ended September 30, 2024 as opposed to Net Income of 1,156,507 the difference primarily attributable to the recognition by the Company of Derivative Income of $ 2,151,755 during the twelve months ended September 30, 2023.

Working Capital

|                     |     | As               
 of September 30, |       2024 |   |     |   |       2023 |   |
|:--------------------|:----|:-----------------|-----------:|:--|:----|:--|-----------:|:--|
| Current assets      |     | $                |    143,351 |   |     | $ |    131,037 |   |
| Current liabilities |     |                  |  5,378,456 |   |     |   |  5,308,003 |   |
| Working capital     |     | $                | (5,235,105 | ) |     | $ | (5,176,966 | ) |

Working capital deficit increased by $ 58,139 from September 30, 2023 to September 30, 2024